Luo Xiaolin, Cao Junya, Zhang Chuyao, Huang He, Liu Jihong
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China; Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China; Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Biochem Biophys Res Commun. 2022 Oct 30;627:68-75. doi: 10.1016/j.bbrc.2022.07.114. Epub 2022 Aug 13.
High-grade serous ovarian cancer (HGSOC) accounts for the majority of deaths caused by epithelial ovarian cancer. The specific molecular changes attributable to the pathogenesis of HGSOC are still largely unknown. TRAF4 has been identified to be up-regulated in certain cancers. However, the role and mechanism of TRAF4 in HGSOC remain unclear. In this study, we aim to explore the prognostic value and function of TRAF4 in HGSOC. Immunohistochemical staining and prognostic analysis were used to estimate the prognosis value of TRAF4 in HGSOC. Cell counting assays, colony formation assays, sphere formation assays and tumorigenic assays were used to explore the function of TRAF4 in ovarian cancer cells. Furthermore, RNA-seq, qPCR and western blotting were performed to investigate the molecular mechanism of TRAF4 in ovarian cancer cells. The results showed that TRAF4 was significantly higher expressed in ovarian cancer than normal ovarian epithelium. Moreover, high expression of TRAF4 was significantly associated with shorter overall survival and recurrence-free survival in HGSOC. Knockdown of TRAF4 significantly inhibited the proliferation and tumorigenicity of ovarian cancer cells, whereas overexpression of TRAF4 promoted the proliferation and tumorigenicity of ovarian cancer cells both in vitro and in vivo. Mechanistically, our study demonstrated that TRAF4 expression was positively correlated with the YAP pathway gene signatures, and the malignant progression induced by TRAF4 was inhibited after silencing YAP signaling by its selective inhibitor. In conclusion, our findings suggested that TRAF4 promoted the malignant progression of ovarian cancer cells by activating YAP pathway and might serve as a prognostic biomarker for HGSOC.
高级别浆液性卵巢癌(HGSOC)占上皮性卵巢癌所致死亡的大多数。HGSOC发病机制所特有的分子变化在很大程度上仍不清楚。已发现TRAF4在某些癌症中上调。然而,TRAF4在HGSOC中的作用和机制仍不清楚。在本研究中,我们旨在探讨TRAF4在HGSOC中的预后价值和功能。采用免疫组织化学染色和预后分析来评估TRAF4在HGSOC中的预后价值。使用细胞计数试验、集落形成试验、成球试验和致瘤试验来探究TRAF4在卵巢癌细胞中的功能。此外,进行RNA测序、qPCR和蛋白质印迹分析以研究TRAF4在卵巢癌细胞中的分子机制。结果显示,TRAF4在卵巢癌中的表达明显高于正常卵巢上皮。此外,TRAF4的高表达与HGSOC患者较短的总生存期和无复发生存期显著相关。敲低TRAF4可显著抑制卵巢癌细胞的增殖和致瘤性,而TRAF4的过表达在体外和体内均促进卵巢癌细胞的增殖和致瘤性。从机制上讲,我们的研究表明TRAF4表达与YAP信号通路基因特征呈正相关,并且在用其选择性抑制剂沉默YAP信号后,TRAF4诱导的恶性进展受到抑制。总之,我们的研究结果表明,TRAF4通过激活YAP信号通路促进卵巢癌细胞的恶性进展,并可能作为HGSOC的预后生物标志物。